Lipids Responsible for Intestinal or Hepatic Disorder

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Samira Sissaoui ◽  
Manon Cochet ◽  
Pierre Poinsot ◽  
Claire Bordat ◽  
Sophie Collardeau-Frachon ◽  
...  
Keyword(s):  
1967 ◽  
Vol 5 (4) ◽  
pp. 15-16

Corticosteroids have been given for almost every hepatic disorder but there have been few controlled trials. They can help in the treatment of inflammatory liver disease, as an adjunct to diuretic therapy, and as a diagnostic test.


2018 ◽  
Vol 19 (11) ◽  
pp. 3452 ◽  
Author(s):  
Shingo Nakamura ◽  
Masayuki Ishihara ◽  
Satoshi Watanabe ◽  
Naoko Ando ◽  
Masato Ohtsuka ◽  
...  

Hydrodynamics-based gene delivery (HGD) is an efficient method for transfecting plasmid DNA into hepatocytes in vivo. However, the resulting gene expression is transient, and occurs in a non-tissue specific manner. The piggyBac (PB) transposon system allows chromosomal integration of a transgene in vitro. This study aimed to achieve long-term in vivo expression of a transgene by performing hepatocyte-specific chromosomal integration of the transgene using PB and HGD. Using this approach, we generated a novel mouse model for a hepatic disorder. A distinct signal from the reporter plasmid DNA was discernible in the murine liver approximately two months after the administration of PB transposons carrying a reporter gene. Then, to induce the hepatic disorder, we first administered mice with a PB transposon carrying a CETD unit (loxP-flanked stop cassette, diphtheria toxin-A chain gene, and poly(A) sites), and then with a plasmid expressing the Cre recombinase under the control of a liver-specific promoter. We showed that this system can be used for in situ manipulation and analysis of hepatocyte function in vivo in non-transgenic (Tg) animals.


2020 ◽  
Vol 58 (4) ◽  
Author(s):  
Ruilin Zhang ◽  
Lasheng Yin ◽  
Jian Chen ◽  
Xuewu Zhang

Research background. Non-alcoholic steatohepatitis is a potentially progressive hepatic disorder that can lead to end-stage liver disease and hepatocellular carcinoma. The inhibitory effects of proteins and hydrolysates from the liver of newborn piglets on hepatic steatosis in oleic-acid-induced HepG2 cells were investigated in vitro. Experimental approach. The extracted proteins from the liver of newborn piglets (NPLP) were hydrolysed with papain, pepsin, trypsin and Alcalase. Based on comparison of different enzyme digestion condition, a protein hydrolysis protocol was established to obtain hydrolysates with lipid-lowering effect. Results and conclusions. NPLH-trypsin (trypsin-digested NPLP hydrolysate) exhibited strong antioxidant activity and possessed good inhibitory effects on lipogenesis and cholesterol accumulation in HepG2 cells at 150 μg/mL, with a triglyceride decrease of (43±3) % and cholesterol decrease of (31±5) %, comparing with 0.75 mM oleic acid induced model. The addition of NPLH-trypsin (300 μg/mL) decreased alanine aminotransferase and aspartate aminotransferase activities and increased superoxide dismutase activity. Novelty and scientific contribution. This study demonstrated that NPLH-trypsin have a potential preventive effect on NAFLD in its early stage, and NPLH-trypsin has potential use as the modulator of lipid overaccumulation disease in food supplements.


1982 ◽  
Vol 43 (12) ◽  
pp. 1319-1324
Author(s):  
Kenichi KUMAZAWA ◽  
Kenji OGAWA ◽  
Yoichi OTANI ◽  
Hirokazu KAWATA ◽  
Shunsuke HAGA ◽  
...  
Keyword(s):  

1987 ◽  
Vol 26 (2) ◽  
pp. 243-248 ◽  
Author(s):  
Katsuhiko TSUKADA ◽  
Masaru OHHASHI ◽  
Takashi ISOBE ◽  
Kazuo MASUKO
Keyword(s):  

2003 ◽  
Vol 81 (1-2) ◽  
pp. 47-49 ◽  
Author(s):  
K IDE ◽  
Y MOMOI ◽  
M MINEGISHI ◽  
M SEKIGUCHI ◽  
K KONNO ◽  
...  

2021 ◽  
Vol 5 (2) ◽  
pp. 904-907
Author(s):  
Liri Çuko ◽  
Fatmir Bilaj ◽  
Durim Çela ◽  
Arlinda Hysenj ◽  
Borana Bakeri ◽  
...  

Alveolar echinococcosis (AE) is caused by the larval form of the tapeworm Echinococcus multilocularis. In humans, E. alveolaris metacestode cells proliferate in the liver inducing a hepatic disorder that mimics liver cancer and can spread to other organs. From 1960 to 1972 mortality was at 70% and 94% after 5 and 10 years of follow-up, respectively. Since then, studies have shown an increasing trend towards improving survival rates [1]. As AE is also spreading to new areas of Eastern Europe, researchers seek to better understand the clinical presentation of pathology, including asymptomatic forms. Clinical case; One 36-year-old woman from Peshkopia has been admitted to the Gastrohephatology department on 20.07.2011 with fatigue, anorexia, dull pain in right hypochondrium, mild epigastric pain, bloating, and weight loss. The epidemiological anamnesis showed that the patient lived in the village and had pets. On physical examination, the patient appeared severely ill with jaundice, massive hepatomegaly, massive mass in the mesogastric area, and anxiety. Laboratory examinations were as follows: Hb 11.1 g/dl, sediment 25 mm/h; leukocytes 6700/mm3; platelets 127000/mm3; prothrombin level 60%, uremia 12.7 mmol/l; creatinine 0.78 mmol /l; ALP 127 U/I; AST 15 U/I; ALT 37 U/I; GGT 131 U/I; bilirubin 3.7 mg/l, albumin 2.8 gr / l, total protein 8.1 gr / l, HbsAg negative, anti-HCV negative. Regarding serology, the titer of anti-echinococcal antibodies was positive (22, n = 11) Conclusions: Clinical presentation and radiologic imaging findings of disseminated alveolar echinococcosis can mimic metastatic malignancy, and diagnosis can be challenging in atypically advanced cases. As the incidence of human alveolar echinococcosis appears to be increasing and, physicians should be aware of alveolar echinococcosis, its epidemiology, and its clinical features.


2018 ◽  
Author(s):  
Ullal Tarini ◽  
Ambrosini Yoko ◽  
Rao Sangeeta ◽  
Webster Cynthia RL ◽  
Twedt David

BackgroundIdiopathic chronic hepatitis (CH) in dogs is a prevalent hepatic disorder. The etiology is poorly understood; however, there is evidence to support an immune-mediated pathogenesis. No literature exists investigating the efficacy of cyclosporine (CsA) therapy for CH in dogs.ObjectivesTo retrospectively evaluate the efficacy and adverse side effects of CsA in the treatment of CH in dogs, and to identify factors that impact response to CsA therapy.Animals48 client-owned dogs diagnosed with CH treated with CsA for at least 2 weeks.MethodsRetrospective review of medical records between the years 2010-2017.ResultsTwenty-two breeds of dogs were included of which 54% were spayed females, 42% neutered males and 4% intact males. Median age was 8.5 years (range, 0.7-14 years). Complete remission (normalization of alanine aminotransferase [ALT]) in response to CsA was attained in 79% of dogs (38/48). Median dose of CsA at the time of remission was 7.9 mg/kg/day (range, 2.5-12.7mg/kg/day) and median time to remission was 2.5 months (range, 0.75-18 months). None of the factors evaluated including clinical score, presence of ascites, hypoalbuminemia, hyperbilirubinemia, prolonged coagulation times, dose, or duration of therapy influenced remission. Common side effects were gastrointestinal signs in 38% (18/48) and gingival hyperplasia in 25% (12/48) of dogs.Conclusion and Clinical ImportanceCsA proved to be a tolerated and effective medication in attaining remission in dogs with idiopathic CH based on normalization of serum ALT. None of the evaluated factors were shown to negatively impact response to CsA or remission of disease.


Kanzo ◽  
1978 ◽  
Vol 19 (5) ◽  
pp. 486-494
Author(s):  
Taichiro SATO ◽  
Shigehiko SHITINO ◽  
Yoshiyuki BAN ◽  
Masashi MAEDA ◽  
Yutaka ISOBE ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document